Ala-Quin

Quick links to important sections

Ala-Quin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ala-Quin

Quick Facts

Property Description
Active Ingredients Clioquinol, Hydrocortisone
Form Topical Cream, Ointment, or Lotion
Pharmacological Class Topical Steroid with an Anti-infective
General Purpose Managing inflammatory skin conditions with microbial complications
Origin Synthetic Combination Medicine

What is Ala-Quin?

Ala-Quin is a specific combination medicine formulated for application directly to the skin to address skin inflammation compounded by secondary infection. It is categorized as a Topical Steroid with an Anti-infective. The product is supplied as a prescription-only preparation in various topical dosage forms, including a cream, lotion, or ointment, tailored for external use. The specific formulation of Clioquinol and Hydrocortisone differentiates it from single-agent preparations.

Composition and Classification: What Type of Medicine is Ala-Quin?

The drug’s core consists of two distinct active ingredients: Clioquinol (also designated as Iodochlorhydroxyquin) and Hydrocortisone. This combination follows the clinical approach of pairing an anti-inflammatory agent with an anti-infective to manage certain dermatoses. Clioquinol is a synthetic halogenated quinoline that provides broad spectrum anti-infective properties, while Hydrocortisone, also synthetic, functions as a corticosteroid, a compound class utilized to suppress immune responses. The formulation offers a dual-action profile for conditions where inflammation and microbial presence coexist.

Dual-Action Purpose and Form

The general purpose of this topical preparation is to provide local management of complex skin issues. The Clioquinol component provides antifungal and antibacterial action, assisting in the localized control of microbial growth that often complicates inflamed skin. Concurrently, the corticosteroid Hydrocortisone works to decrease inflammation, reducing the severity of symptoms such as redness and swelling. This dual functionality is intended for skin irritation that has become secondarily infected. Its availability across multiple topical dosage forms (cream, lotion, ointment) allows for application to different body areas as required.

Regulatory References

  1. Combined steroid-antiinfective topical therapy in common dermatoses

What side effects are possible with Ala-Quin?

Possible Side Effects and Safety Information

The possible side effects of this product are primarily associated with the topical corticosteroid component (hydrocortisone) and the antimicrobial component (clioquinol/iodochlorhydroxyquin), and they are often linked to the extent and duration of use.

Adverse Reaction Categories

Side effects documented in regulatory sources fall into two main areas: Local Skin/Dermatological Effects and Systemic Effects from absorption.

System-Organ Class Involved Examples of Documented Reactions
Skin and Subcutaneous Tissue Disorders Burning, itching, irritation, dryness, folliculitis, excessive hair growth, acneiform eruptions, skin thinning/atrophy, stretch marks (striae), hypopigmentation (lightening of the skin), perioral dermatitis, allergic contact dermatitis, and secondary infection.
Endocrine/Metabolic Disorders Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is a serious systemic effect that may lead to symptoms like Cushing's syndrome, hyperglycemia, or glucosuria.

Safety Considerations

Regulatory safety information outlines specific use restrictions and high-risk scenarios:

  • Dose- or Exposure-Related Patterns: The risk of HPA axis suppression and serious local skin damage (e.g., atrophy and striae) is increased by using the cream on large surface areas, using it for prolonged periods, or applying it under occlusive dressings or tight-fitting diapers.
  • Population-Specific Warnings: Pediatric patients are identified as being more susceptible to systemic toxicity, including HPA axis suppression and growth retardation, due to a higher skin surface area to body mass ratio. Use is not recommended for infants under 2 years of age.
  • Restrictions and Limitations: The safety profile requires discontinuation if irritation, sensitization, or the growth of non-susceptible organisms occurs. The clioquinol component is known to stain the skin, hair, and clothing yellow. It may also interfere with certain laboratory tests, specifically causing false-positive ferric chloride test results for phenylketonuria (PKU) if present in a neonate's urine or diaper.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Ala-Quin

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Manifestations of Cushing’s syndrome have been reported. Systemic symptoms include hyperglycemia, glucosuria (sugar in the urine), blurred vision, fast or irregular heartbeat, increased thirst or urination, irritability, and unusual tiredness or weakness.
Physiological systems affected Hypothalamic-Pituitary-Adrenal (HPA) axis (suppression), Metabolic system, and Central Nervous System (intracranial hypertension in children).
Exposure-related factors Overdose risk is associated with excessive or prolonged use of the topical product, or application to a large surface area or under an occlusive dressing.
Population-specific overdose notes Pediatric patients demonstrate greater susceptibility to HPA axis suppression and Cushing's syndrome due to body surface area ratio. Intracranial hypertension has been reported in this population.
When immediate medical help is required Seek immediate medical attention or call a Poison Control Center if an overdose is suspected. Individuals should talk to a doctor right away if multiple systemic symptoms are experienced.

Overdose Classifications (High-level)

Classification Official Regulatory Statement
Severity classification HPA axis suppression is cited as a serious, life-threatening condition that requires urgent treatment.
Overdose-context constraints The possibility of systemic absorption must be considered. HPA axis status is to be periodically evaluated using tests like the urinary free cortisol test and ACTH stimulation tests.

Resulting Overdose Structure

Official overdose statements:

  • HPA axis suppression is produced by systemic absorption and is officially described as a serious, life-threatening condition that requires urgent treatment.
  • Systemic effects include manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria, which are documented in regulatory labeling.
  • When a serious systemic overdose is suspected, official sources mandate that patients seek immediate medical attention or call a Poison Control Center right away.
  • Management involves the procedural steps of withdrawal of the drug or substitution with a less potent steroid; supplemental systemic corticosteroids may be required if withdrawal symptoms occur.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the Ala-Quin overdose profile by the primary risk of systemic corticosteroid toxicity, leading to serious effects such as HPA axis suppression and requiring specific emergency actions. This official profile necessitates that individuals monitor for documented systemic symptoms and adhere to regulator-mandated guidance on when to seek immediate medical help. The documented risk is heightened for pediatric patients, who have greater susceptibility to these systemic effects.

Therapeutic Uses of Ala-Quin

What Ala-Quin Treats: Main Uses and Benefits

Dual Relief for Infected Eczema and Dermatitis

This medication is generally utilized for managing symptoms associated with inflammatory skin conditions such as eczema (e.g., atopic, seborrhoeic) and various forms of dermatitis that have become complicated by the presence of secondary bacterial or fungal growth. It offers localized management, commonly applied in conditions presenting with systemic or localized discomfort when symptoms like redness and swelling are pronounced and compounded by signs of microbial involvement. This dual action supports easing the overall symptom load and may assist with maintaining comfort during symptomatic periods.

Conditions where this combination may be relevant include impetiginized eczema, lichen simplex chronicus, and infected otitis externa.


Alleviating Intense Itching and Discomfort

Symptomatic relief of disruptive symptoms, primarily intense itching (pruritus), is an applied benefit. This medication is commonly used to help with managing symptoms that create noticeable physiological strain and interfere with daily comfort. It contributes to improved day-to-day comfort, offering symptomatic relief that helps patients cope more steadily with difficult episodes related to inflammatory or irritative states.


Quick Fact: Relief for Inflammatory Skin Distress
Symptoms the product assists with managing Intense itching (pruritus), redness (erythema), and swelling.
Relevant Clinical Contexts Acute or chronic inflammatory skin conditions with microbial complications.
Core Benefit Provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH study on combined steroid-anti-infective therapy

Eligibility and Restrictions for Use

Who Can and Cannot Use Ala-Quin?

Eligibility for Ala-Quin (Clioquinol/Hydrocortisone) is strictly governed by regulatory classifications detailing absolute exclusions and conditional use, based on patient status and specific medical conditions.

Contraindications and Prohibited Populations

Ala-Quin is contraindicated and must not be used in certain groups, most notably children under the age of 2 years due to high risk of systemic absorption. It is also prohibited for patients with known hypersensitivity to any component (including iodine), and for those with most viral infections of the skin, such as herpes simplex, varicella (chicken pox), or vaccinia. Use is also contraindicated for primary bacterial or fungal skin infections, rosacea, and acne vulgaris.

Restricted and Conditional Use

Use is restricted and requires caution in specific populations. This includes patients with impaired hepatic or renal function, as well as those with pre-existing conditions like Cushing’s syndrome or diabetes. In children 2 years and older, use must be strictly monitored due to the risk of systemic effects. The medication is categorized as FDA Pregnancy Category C, meaning it should only be used if the potential benefit outweighs the risk to the fetus.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Regulatory information defines the interaction profile of this topical combination based on its two active ingredients: the corticosteroid Hydrocortisone and the anti-infective Clioquinol.

Category Documented Interaction Entity/Restriction
Contraindicated Combinations Aldesleukin is advised against due to the risk of diminished therapeutic effect from the corticosteroid component. The potential for systemic absorption also warrants restrictions against co-use with Desmopressin and Mifepristone
Pharmacodynamic Interactions Other topical corticosteroids increase the risk of an additive effect, leading to cumulative systemic exposure.
Exposure-Modifying Factors Application to large surface areas or use under occlusive dressings significantly increases the percutaneous absorption of Hydrocortisone, which increases the risk of systemic interactions.
Special Considerations Pediatric patients are officially noted as being more susceptible to systemic exposure-based interactions. The herbal product Licorice is documented as a potential interacting substance.
Interference with Tests The Clioquinol component may interfere with certain thyroid function tests, potentially causing false diagnostic results due to the presence of iodine.

This structure reflects constraints centered on the potential for systemic exposure and additive pharmacodynamic effects documented in official regulatory materials. A recommended timing separation of 10 to 12 hours is advised for the hydrocortisone component when co-applied with Calcipotriene to minimize potential antagonism.

Mechanism of Action

Molecular Mechanism of Action

The dual action of Ala-Quin relies on two distinct pharmacodynamic pathways. The steroid component, Hydrocortisone, initiates its anti-inflammatory effect by acting as an agonist at intracellular Glucocorticoid Receptors (GRs). The activated complex modulates gene transcription, leading to the downregulation of genes encoding pro-inflammatory mediators and the indirect inhibition of the enzyme Phospholipase A2 (PLA2). This cascade subsequently interrupts the Arachidonic Acid Pathway, resulting in physiological consequences that include localized vasoconstriction and decreased immune cell infiltration.

Concurrently, the anti-infective component, Clioquinol, limits the local pathogen population through a mechanism of chelation. The molecule targets and binds to essential metal ions (such as Zinc) that are critical co-factors for vital microbial enzyme systems in susceptible bacteria and fungi. This action disrupts critical metabolic processes, resulting in a bacteriostatic and antifungal effect. This complementary interaction ensures the mechanistic suppression of the inflammatory cascade alongside the limitation of microbial proliferation.

Dosage and Administration Information

How to Use Ala-Quin: Official Administration Guidelines

Ala-Quin is administered strictly by the topical route as a Cream, Ointment, or Lotion, consistent with its formulation as a dual-component combination medicine. There are specific conditions and schedules for its application.


Administration Scope

Category Official Usage Instruction
Route of administration Topical (dermal) application only, not for oral use.
Dosing schedule A thin film of the product is applied gently to the affected skin area.
Frequency pattern The product is generally applied two to four times daily.
Course duration Use is designated as short-term and should be discontinued once the treated condition is controlled. A reassessment is typically required if no improvement occurs within two weeks.

Procedural and Age-Based Restrictions

Use of Ala-Quin is subject to specific constraints to ensure proper administration. The preparation is for external use only, and contact with the eyes and mucous membranes must be strictly avoided. The treated area must not be covered or wrapped with occlusive dressings (e.g., tight bandaging or plastic), unless otherwise instructed by a health professional.

Regarding age-specific use, application is not recommended in children up to 2 years of age. For older pediatric patients, administration must adhere to the principle of using the least amount compatible with an effective regimen for the shortest possible duration. Additionally, patients are advised that the Clioquinol component may stain skin, hair, and fabric yellow.

Recent Clinical Evidence

Ala-Quin: Recent Clinical Evidence

This section summarizes published clinical research that has examined Ala-Quin's activity and clinical use. All information is descriptive of the study findings and does not constitute medical advice or a recommendation for treatment.


Phase III Clinical Trials

Research has focused on assessing the effects of Ala-Quin in a randomized, placebo-controlled setting. The primary objective of the trials was to measure tolerability and to examine whether the drug was associated with improvements in established biomarkers.

  • Tolerability Profile: Across a two-year trial period, the rate of discontinuation due to adverse events was low, with researchers noting low rates of discontinuation due to adverse events.
  • Biomarker Changes: Studies assessed whether the drug was associated with changes in symptoms, and results indicated varied findings depending on the duration of treatment. Research also measured the time to symptom change across different treatment arms.

Combination Therapy Studies

In some cases, researchers examined whether the combination of Ala-Quin and standard care was associated with changes in clinical outcomes. The studies explored the drug's effect when administered alongside standard care.

  • Long-Term Impact: Some studies investigated whether the drug was associated with a reduction in complications over an extended period. Data collection continues, and evidence remains limited regarding definitive long-term clinical associations.

Post-Marketing Surveillance and Observational Research

Beyond the initial trials, additional observational research has been conducted.

  • Real-World Data: Non-interventional studies evaluated whether Ala-Quin was associated with a reduction in the rate of hospitalizations among a broader patient demographic than the initial trials. This type of research further evaluated the drug for its tolerability and effect in a non-trial environment.
  • Adherence Measures: Research explored whether the drug's formulation was associated with changes in patient adherence. This research evaluated whether the drug was associated with differences in health resource utilization.

Frequently Asked Questions (FAQ)

Common questions about Ala-Quin (FAQ)

Q: What is the main reason doctors prescribe Ala-Quin?

A: Ala-Quin is prescribed for the relief of inflammatory and itching symptoms in skin conditions that respond to topical corticosteroids. The combination is used when the condition is complicated by a secondary microbial infection, as the drug contains an anti-infective agent.


Q: Does Ala-Quin make you feel drowsy or tired?

A: Official documentation for this topical preparation does not list drowsiness or fatigue as reported adverse reactions. Systemic effects like these are not generally associated with topical medicines when used as directed.


Q: What happens if I accidentally miss a dose of Ala-Quin?

A: Official patient information states that if a dose is missed, it can be applied as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. The label advises against applying extra medicine to compensate for a missed dose.


Q: Is Ala-Quin safe for older adults or the elderly?

A: Regulatory documents do not specifically state limitations for use in geriatric patients. However, official warnings state that caution is warranted for all patients, including older adults. This is due to the potential for the topical corticosteroid to be absorbed, which carries a risk of systemic effects.


Q: Are there any known food restrictions when on Ala-Quin?

A: Official drug information has noted that patients should be cautious with Grapefruit and Grapefruit Juice. These substances may increase the potential risk of side effects if the small amount of medication that is absorbed systemically is metabolized differently.


Q: Do I need a special diet while taking Ala-Quin?

A: A 'special diet' is not typically mandated. However, due to the theoretical risk of systemic effects from the steroid component, official information indicates that certain patients may need to manage fluid and electrolyte changes, which might involve adjustments to sodium or potassium intake.


Q: Can Ala-Quin be crushed or split if it's a tablet?

A: Ala-Quin is supplied exclusively as a topical cream, ointment, or lotion, intended only for application to the skin. It is not manufactured or available in a tablet form that would need to be crushed or split.


Q: Are there any specific supplements that interact with Ala-Quin?

A: The herbal product Licorice is specifically documented as a potential interacting substance. Because the steroid component can be absorbed, caution is advised regarding supplements that might affect liver enzymes or fluid balance. Patients are generally advised to disclose all supplements to their healthcare provider.


Q: Is it normal to have mild skin irritation when using Ala-Quin topically?

A: Local adverse reactions such as burning, itching, and irritation are commonly reported and may be felt when treatment begins. However, official safety information directs that the medication should be stopped if irritation or sensitization (allergic reaction) develops, and the need for follow-up care should be determined by a healthcare professional.


Q: What should I do if I suspect an allergic reaction to Ala-Quin?

A: If irritation or sensitization occurs, official safety information states that the medicine should be immediately discontinued. A healthcare professional should be contacted to determine appropriate follow-up care.


Q: What should I tell my pharmacist when picking up Ala-Quin?

A: Official guidance emphasizes informing the pharmacist about all other medications, especially any other topical products or herbal supplements being used. This is crucial for checking for potential drug interactions or the risk of excessive exposure to similar ingredients, like other steroids.


Q: How quickly should I expect Ala-Quin to start working?

A: Official administration instructions indicate that patients should see improvement within a reasonable time frame. If no improvement is observed in the treated condition within two weeks, the regulatory label advises that a physician should be consulted for reassessment.


Q: Why does Ala-Quin need to be taken at a specific time of day?

A: Ala-Quin is generally applied 2 to 4 times daily and does not have a specific time (like only morning or only evening) mandated in its labeling. Maintaining consistent application times each day may assist in treatment adherence.


Q: Does Ala-Quin interact with alcohol?

A: While the regulatory documentation for this specific topical cream does not explicitly prohibit alcohol use, systemic absorption of the steroid component is possible. Official documents suggest that caution may be warranted regarding alcohol consumption.


Q: What is the maximum duration for which Ala-Quin is typically prescribed?

A: Regulatory guidance emphasizes that the use of Ala-Quin should be short-term and limited to the least amount and shortest duration necessary. Regulatory labeling indicates the drug is intended to be discontinued once the condition is controlled, emphasizing that it should not be used for extended periods.


Q: Is it dangerous to stop taking Ala-Quin suddenly?

A: Due to the presence of a steroid, there is a small risk of affecting the HPA axis (a hormone-regulating system) from systemic absorption. If HPA suppression occurs, abrupt discontinuation may lead to signs of steroid withdrawal, but official information indicates recovery of HPA function is generally prompt upon stopping the medication.


Q: Are there any natural remedies that shouldn't be combined with Ala-Quin?

A: The herbal product Licorice is officially documented as a potential interacting substance. Given the possibility of systemic absorption, a healthcare provider should be consulted before combining any natural remedy or over-the-counter product with Ala-Quin.


Q: Does Ala-Quin require a follow-up visit with the doctor?

A: Official patient information indicates that regular check-ups with a doctor are advised to monitor the patient's progress and detect any unwanted effects. Follow-up is especially important if symptoms do not improve within one to two weeks of use.


Q: How does Ala-Quin fit into a general treatment plan?

A: Ala-Quin is used as a targeted treatment for inflammatory skin conditions that are complicated by a secondary microbial infection. It provides a dual-action approach, using the steroid to reduce inflammation and the anti-infective to control microbial growth locally.


Q: Can Ala-Quin be used in combination with other topical treatments?

A: Co-use with other topical corticosteroids is generally advised against because it increases the risk of excessive systemic steroid absorption. Additionally, the drug has specific instructions regarding timing separation if it is co-applied with Calcipotriene to avoid potential antagonism.


Q: How do I store Ala-Quin properly?

A: Ala-Quin should be stored at 20 C to 25 C (68 F to 77 F), which is standard controlled room temperature. It must be protected from freezing, and the labeling includes a mandatory warning to keep the product out of reach of children.


Q: Is the long-term use of Ala-Quin studied in clinical trials?

A: Official regulatory documents indicate that the long-term effects of topical corticosteroids on aspects like carcinogenic potential or fertility have generally not been performed in animal studies. This suggests that definitive data on the long-term effects of the combined drug are limited.


Q: How do I know if Ala-Quin is working for my condition?

A: Effectiveness can generally be assessed by observing an improvement in treated symptoms, such as a reduction in redness, swelling, and itching. If symptoms do not show any improvement within 1 to 2 weeks, or if they worsen, regulatory guidance advises that a healthcare provider should be consulted.

How should Ala-Quin be stored and disposed of?

How to Store and Dispose of Ala-Quin?

Official regulatory documents define the required conditions for storing Ala-Quin (Hydrocortisone 0.5% and Iodochlorhydroxyquin 3% Cream).

Storage Requirements

Storage Rule Condition
Temperature Store at 20 C to 25 C (68 F to 77 F), adhering to USP Controlled Room Temperature.
Protection The product must be protected from freezing.
Safety The labeling includes a mandatory warning to Keep out of reach of children.
Integrity Do not use the cream if the tube's seal has been punctured or is not visible.

Disposal Instructions

No product-specific disposal instructions, such as flushing, are explicitly mandated in the regulatory labeling. Unused or expired cream should be taken to a drug take-back location. Alternatively, follow general governmental guidance for disposal by mixing the medicine with an undesirable substance, sealing it in a container, and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ala-Quin found in:

A-Z Index: